Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (PDX samples from different disease statuses)

ABSTRACT: Human PDX cells were enriched from mice treated with vehicle control or venetoclax + azacitidine

ORGANISM(S): Homo sapiens

PROVIDER: GSE301872 | GEO | 2026/07/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP [eCLIPseq]

Project description:eCLIP-seq was performed using CAL-1 cells treated with control (DMSO) or venetoclax+azacitidine (VenAza) for 6 hours to identify KHSRP-interacting RNAs

2026-07-07 | GSE301866 | GEO

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (PDX samples from different disease statuses)

Project description:Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (PDX samples from different disease statuses)

| PRJNA1287680 | ENA

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (KHSRP knockdown in CAL-1 cells)

Project description:KHSRP was knocked down in CAL-1 cells by CRISPR interference, then RNA-seq was performed in control and KHSRP knockdown cells to assess differentially expressed genes.

2025-10-28 | GSE301870 | GEO

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (AML patient samples)

Project description:Acute myeloid leukemia (AML) remains highly prone to relapse driven by therapy-persistent residual cells. To discover specific vulnerabilities in this population, we performed genome-wide CRISPR interference screens in AML cells treated with multiple agents. KHSRP was the top hit, whose depletion sensitized AML cells to therapy and substantially prolonged survival in treated AML-bearing mice. Profiling in vivo residual disease after therapy identified downregulation of the vitamin C and uric acid transporter SLC23A1 as a resistance mechanism. KHSRP depletion restored SLC23A1 through a previously unrecognized function by preventing ZC3H4-mediated nuclear mRNA degradation. KHSRP depletion therefore enhanced the synergistic cytotoxicity of vitamin C and uric acid, particularly in therapy-persistent leukemia cells. Re-expression of TET2 overrode the chemosensitizing effect of KHSRP depletion in TET2-mutant leukemia, suggesting that KHSRP phenotypes were linked to vitamin C and uric acid-mediated TET activation. These findings nominate targeting KHSRP to enhance treatment efficacy and selectively eradicate residual AML.

2026-07-10 | GSE337663 | GEO

IMPRINTS-CETSA Venetoclax in Kasumi-1 cells, 1h incubation

Project description:IMPRINTS-CETSA data acquisition of Kasumi-1 cells treated with Vehicle (DMSO), Venetoclax, Decitabine, Azacitidine and Azacitidine+Venetoclax using TMT 16 plex.

2024-10-23 | PXD056183 | Pride

IMPRINTS-CETSA Venetoclax in Kasumi-1 cells, 6h incubation

Project description:IMPRINTS-CETSA data acquisition of Kasumi-1 cells treated with Vehicle (DMSO), Venetoclax, Decitabine, Azacitidine and Azacitidine+Venetoclax using TMT 16 plex.

2024-10-23 | PXD056189 | Pride

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP [eCLIPseq]

Project description:Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP [eCLIPseq]

| PRJNA1287679 | ENA

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (KHSRP knockdown in CAL-1 cells)

Project description:Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (KHSRP knockdown in CAL-1 cells)

| PRJNA1287681 | ENA

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (AML patient samples)

Project description:Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (AML patient samples)

| PRJNA1490549 | ENA

Inducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL

Project description:Clinically relevant methods are not available that prioritize and validate potential therapeutic targets for individual tumors from the vast amount of tumor descriptive expression data. We established inducible transgene expression in clinically relevant patient-derived xenograft (PDX) models in vivo to fill this gap. With this technique at hand, we analyzed the role of the transcription factor Krüppel-like factor 4 (KLF4) in B-cell acute lymphoblastic leukemia (B-ALL) PDX models at different disease stages. In competitive preclinical in vivo trials, we found that re-expression of wild type KLF4 reduced the leukemia load in PDX models of B-ALL, with the strongest effects being observed after conventional chemotherapy in minimal residual disease (MRD). A nonfunctional KLF4 mutant had no effect on this model. The re-expression of KLF4 sensitized tumor cells in the PDX model towards systemic chemotherapy in vivo. It is of major translational relevance that azacitidine upregulated KLF4 levels in the PDX model and a KLF4 knockout reduced azacitidine-induced cell death, suggesting that azacitidine can regulate KLF4 re-expression. These results support the application of azacitidine in patients with B-ALL as a therapeutic option to regulate KLF4. Genetic engineering of PDX models allows the examination of the function of dysregulated genes like KLF4 in a highly clinically relevant translational context, and it also enables the selection of therapeutic targets in individual tumors and links their functions to clinically available drugs, which will facilitate personalized treatment in the future.

2020-06-27 | GSE153382 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data